Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP: BICX )

1.300 +0.090 (+7.44%)
Streaming Delayed Price Updated: 1:04 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,855
Open 1.205
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 1.210
Today's Range 1.205 - 1.300
52wk Range 0.6502 - 2.220
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioCorRx Reports Business Update for the Third Quarter of 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
Exposures Death
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety

Performance

YTD
+18.18%
+18.18%
1 Month
-17.72%
-17.72%
3 Month
-22.62%
-22.62%
6 Month
-27.37%
-27.37%
1 Year
-27.78%
-27.78%

More News

Read More
BioCorRx Reports Business Update for the Second Quarter of 2023
Via NewMediaWire
Exposures Product Safety
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Via NewMediaWire
Topics Death
Exposures Death Product Safety
Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
BioCorRx Provides Business Update for the First Quarter of 2023
Via NewMediaWire
BioCorRx Provides Business Update for 2022
Via NewMediaWire
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Via NewMediaWire
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
Via NewMediaWire
Exposures Product Safety
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
Via NewMediaWire
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
Via NewMediaWire
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Clear Channel Outdoor, Archer Aviation And These 2 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States
Via NewMediaWire
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
Via NewMediaWire
BioCorRx Provides Business Update for the Third Quarter of 2022
Via NewMediaWire
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via NewMediaWire
Exposures Product Safety
BioCorRx Provides Business Update for the Second Quarter of 2022
Via NewMediaWire
Exposures Product Safety
Meet BioCorRx: The Biotechnology Firm Taking A Specialized Approach To Treating Addictive Disorders
Via Benzinga
BioCorRx to Participate in the Benzinga All Access Event on July 15th
Via NewMediaWire
BioCorRX Inc. Discusses BICX104 Human Trials and 2B3D Metaverse Partnership with The Stock Day Podcast
Via Newsfile
Exposures Product Safety
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Via NewMediaWire
Topics Death
Exposures Death
BioCorRx Featured on LiveNOW from FOX
Via NewMediaWire
Exposures Product Safety
BioCorRx to Present at the LD Micro Invitational XII on June 7th
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.